jnj:PulmonaryHypertensionMember
2024-12-30
2025-03-30
0000200406
country:US
jnj:UPTRAVIMember
jnj:InnovativeMedicineMember
jnj:PulmonaryHypertensionMember
2024-01-01
2024-03-31
0000200406
us-gaap:NonUsMember
jnj:UPTRAVIMember
jnj:InnovativeMedicineMember
jnj:PulmonaryHypertensionMember
2024-12-30
2025-03-30
0000200406
us-gaap:NonUsMember
jnj:UPTRAVIMember
jnj:InnovativeMedicineMember
jnj:PulmonaryHypertensionMember
2024-01-01
2024-03-31
0000200406
jnj:UPTRAVIMember
jnj:InnovativeMedicineMember
jnj:PulmonaryHypertensionMember
2024-12-30
2025-03-30
0000200406
jnj:UPTRAVIMember
jnj:InnovativeMedicineMember
jnj:PulmonaryHypertensionMember
2024-01-01
2024-03-31
0000200406
country:US
jnj:OtherMember
jnj:InnovativeMedicineMember
jnj:PulmonaryHypertensionMember
2024-12-30
2025-03-30
0000200406
country:US
jnj:OtherMember
jnj:InnovativeMedicineMember
jnj:PulmonaryHypertensionMember
2024-01-01
2024-03-31
0000200406
us-gaap:NonUsMember
jnj:OtherMember
jnj:InnovativeMedicineMember
jnj:PulmonaryHypertensionMember
2024-12-30
2025-03-30
0000200406
us-gaap:NonUsMember
jnj:OtherMember
jnj:InnovativeMedicineMember
jnj:PulmonaryHypertensionMember
2024-01-01
2024-03-31
0000200406
jnj:OtherMember
jnj:InnovativeMedicineMember
jnj:PulmonaryHypertensionMember
2024-12-30
2025-03-30
0000200406
jnj:OtherMember
jnj:InnovativeMedicineMember
jnj:PulmonaryHypertensionMember
2024-01-01
2024-03-31
0000200406
country:US
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-12-30
2025-03-30
0000200406
country:US
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-01-01
2024-03-31
0000200406
us-gaap:NonUsMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-12-30
2025-03-30
0000200406
us-gaap:NonUsMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-01-01
2024-03-31
0000200406
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-12-30
2025-03-30
0000200406
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-01-01
2024-03-31
0000200406
country:US
jnj:EDURANTrilpivirineMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-12-30
2025-03-30
0000200406
country:US
jnj:EDURANTrilpivirineMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-01-01
2024-03-31
0000200406
us-gaap:NonUsMember
jnj:EDURANTrilpivirineMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-12-30
2025-03-30
0000200406
us-gaap:NonUsMember
jnj:EDURANTrilpivirineMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-01-01
2024-03-31
0000200406
jnj:EDURANTrilpivirineMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-12-30
2025-03-30
0000200406
jnj:EDURANTrilpivirineMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-01-01
2024-03-31
0000200406
country:US
jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-12-30
2025-03-30
0000200406
country:US
jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember